|
2023 Conference Publication HER2 in situ hybridization testing in breast cancer: applying algorithm-assisted assessment to reduce interobserver variability in difficult casesGough, Madeline, Liu, Cheng, Srinivasan, Bhuvana, Wilkinson, Lisa, Dunk, Louisa, Yang, Yuanhao, Tuffaha, Haitham, Kryza, Thomas, Hooper, John D., Lakhani, Sunil R. and Snell, Cameron Edward (2023). HER2 in situ hybridization testing in breast cancer: applying algorithm-assisted assessment to reduce interobserver variability in difficult cases. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.e13561 |
|
2023 Journal Article Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancerDutt, Mriga, Hartel, Gunter, Richards, Renee S., Shah, Alok K., Mohamed, Ahmed, Apostolidou, Sophia, Gentry‐Maharaj, Aleksandra, Hooper, John D., Perrin, Lewis C., Menon, Usha, Hill, Michelle M. and Australian Ovarian Cancer Study Group (2023). Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer. Proteomics - Clinical Applications, 17 (4) 2200114, 1-16. doi: 10.1002/prca.202200114 |
|
2023 Journal Article Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinomaRaninga, Prahlad V., He, Yaowu, Datta, Keshava K., Lu, Xue, Maheshwari, Uma R., Venkat, Pooja, Mayoh, Chelsea, Gowda, Harsha, Kalimutho, Murugan, Hooper, John D. and Khanna, Kum Kum (2023). Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma. Molecular Therapy, 31 (3) 212011, 729-743. doi: 10.1016/j.ymthe.2022.12.011 |
|
2023 Conference Publication Abstract P4-07-26: Development of CDCP1-targeting antibody-drug conjugate for Triple negative and metastatic breast cancerGough, Madeline, Khan, Tashbib, Kwah, Kayden, He, Yaowu, Ratnayake, Gishan, Pyke, Christopher, Snell, Cameron, Hooper, John and Kryza, Thomas (2023). Abstract P4-07-26: Development of CDCP1-targeting antibody-drug conjugate for Triple negative and metastatic breast cancer. 2022 San Antonio Breast Cancer Symposium, San Antonio, TX United States, 6-10 December 2022. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.sabcs22-p4-07-26 |
|
2023 Journal Article Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancerLyons, Nicholas, Giri, Rabina, Begun, Jakob, Clark, David A, Proud, David, He, Yaowu, Hooper, John and Kryza, Thomas (2023). Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancer. Antioxidants and Redox Signaling, 39 (1-3), 186-205. doi: 10.1089/ars.2022.0127 |
|
2023 Journal Article Missing parameters in malignant polyp histology reports: can appropriate decisions be made?Zammit, Andrew P., Brown, Ian, Hooper, John D., Clark, David A. and Riddell, Andrew D. (2023). Missing parameters in malignant polyp histology reports: can appropriate decisions be made?. Pathology, 55 (1), 58-63. doi: 10.1016/j.pathol.2022.06.007 |
|
2023 Journal Article In comparison with polypectomy, colorectal resection is associated with improved survival for patients diagnosed with malignant polypsZammit, Andrew P., Hooper, John D., Brown, Ian, Clark, David A. and Riddell, Andrew D. (2023). In comparison with polypectomy, colorectal resection is associated with improved survival for patients diagnosed with malignant polyps. Colorectal Disease, 25 (2), 261-271. doi: 10.1111/codi.16369 |
|
2023 Journal Article Malignant polyps in the COVID ‐19 era: a population‐based analysisZammit, Andrew P., Brown, Ian, Hooper, John D., Clark, David A. and Riddell, Andrew D. (2023). Malignant polyps in the COVID ‐19 era: a population‐based analysis. ANZ Journal of Surgery, 93 (4), 932-938. doi: 10.1111/ans.18253 |
|
2023 Journal Article Management of high and low risk malignant polyps – a population wide analysisZammit, Andrew P., Panahi, Seyed E., Brown, Ian, Hooper, John D., Clark, David A. and Riddell, Andrew D. (2023). Management of high and low risk malignant polyps – a population wide analysis. Colorectal Disease, 25 (1), 66-74. doi: 10.1111/codi.16328 |
|
2022 Journal Article CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitorsLu, Xue, He, Yaowu, Johnston, Rebecca L., Nanayakarra, Devathri, Sankarasubramanian, Sivanandhini, Lopez, J. Alejandro, Friedlander, Michael, Kalimutho, Murugan, Hooper, John D., Raninga, Prahlad V. and Khanna, Kum Kum (2022). CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. Journal of Experimental and Clinical Cancer Research, 41 (1) 355, 1-17. doi: 10.1186/s13046-022-02570-4 |
|
2022 Conference Publication Development of antibody-drug conjugates targeting the CDCP1 receptor for the treatment of Triple negative and metastatic breast cancerGough, M., Kwah, K., Khan, T., He, Y., Pyke, C., Ratnayake, G., Snell, C., Hooper, J. and Kryza, T. (2022). Development of antibody-drug conjugates targeting the CDCP1 receptor for the treatment of Triple negative and metastatic breast cancer. 13th European Breast Cancer Conference (EBCC-13), Barcelona, Spain, 16-18 November 2022. Oxford, United Kingdom: Elsevier. doi: 10.1016/s0959-8049(22)01571-4 |
|
2022 Journal Article Timing of surveillance colonoscopy following malignant colorectal polypectomy in QueenslandZammit, Andrew P., Brown, Ian, Hooper, John D., Clark, David A. and Riddell, Andrew D. (2022). Timing of surveillance colonoscopy following malignant colorectal polypectomy in Queensland. ANZ Journal of Surgery, 93 (3), 606-611. doi: 10.1111/ans.18069 |
|
2022 Journal Article CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapyKhan, Tashbib, Lyons, Nicholas J., Gough, Madeline, Kwah, Kayden K.X., Cuda, Tahleesa J., Snell, Cameron E., Tse, Brian W., Sokolowski, Kamil A., Pearce, Lesley A., Adams, Timothy E., Rose, Stephen E., Puttick, Simon, Pajic, Marina, Adams, Mark N., He, Yaowu, Hooper, John D. and Kryza, Thomas (2022). CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy. Theranostics, 12 (16), 6915-6930. doi: 10.7150/thno.78171 |
|
2022 Conference Publication EP-369 examining EphA2 expression in colorectal cancerLyons, Nicholas, Hooper, John, Kryza, Thomas, Clark, David and Riddell, Andrew (2022). EP-369 examining EphA2 expression in colorectal cancer. Association of Surgeons of Great Britain and Ireland Annual Congress, Liverpool, United Kingdom, 2022. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/bjs/znac245.094 |
|
2022 Conference Publication Intraoperative identification of colorectal cancer lesions using indocyanine green labelled antibodies in preclinical murine modelsLyons, Nicholas, Hooper, John, Clark, David, Riddell, Andrew and Kryza, Thomas (2022). Intraoperative identification of colorectal cancer lesions using indocyanine green labelled antibodies in preclinical murine models. Association of Surgeons of Great Britain and Ireland, Annual Congress, Liverpool, United Kingdom, 3-5 May 2022. Oxford, United Kingdom: Oxford University Press . doi: 10.1093/bjs/znac245.093 |
|
2022 Journal Article A population‐based study of the management of rectal malignant polyps and the use of trans‐anal surgeryZammit, Andrew P., Brown, Ian, Hooper, John D., Clark, David A. and Riddell, Andrew D. (2022). A population‐based study of the management of rectal malignant polyps and the use of trans‐anal surgery. ANZ Journal of Surgery, 92 (11), 2949-2955. doi: 10.1111/ans.17917 |
|
2022 Journal Article Protease‐activated receptor‐2 dependent and independent responses of bone cells to prostate cancer cell secretory productsPagel, Charles N., Kularathna, Pamu K., Sanaei, Reza, Young, Neil D., Hooper, John D. and Mackie, Eleanor J. (2022). Protease‐activated receptor‐2 dependent and independent responses of bone cells to prostate cancer cell secretory products. The Prostate, 82 (6), 723-739. doi: 10.1002/pros.24316 |
|
2022 Journal Article Erratum: Alpha-Tomatine Attenuation of In Vivo Growth of Subcutaneous and Orthotopic Xenograft Tumors of Human Prostate Carcinoma PC-3 Cells Is Accompanied by Inactivation of Nuclear Factor-Kappa B Signaling (PLoS ONE (2013) 8:2 (e57708) DOI: 10.1371/journal.pone.0057708)Lee, Sui-Ting, Wong, Pooi-Fong, He, Hui, Hooper, John David and Mustafa, Mohd Rais (2022). Erratum: Alpha-Tomatine Attenuation of In Vivo Growth of Subcutaneous and Orthotopic Xenograft Tumors of Human Prostate Carcinoma PC-3 Cells Is Accompanied by Inactivation of Nuclear Factor-Kappa B Signaling (PLoS ONE (2013) 8:2 (e57708) DOI: 10.1371/journal.pone.0057708). PLoS ONE, 17 (5 May) e0268234. doi: 10.1371/journal.pone.0268234 |
|
2022 Journal Article Patient and pathological predictors of management strategy for malignant polyps following polypectomy: a systematic review and meta-analysisZammit, Andrew P., Lyons, Nicholas J., Chatfield, Mark D., Hooper, John D., Brown, Ian, Clark, David A. and Riddell, Andrew D. (2022). Patient and pathological predictors of management strategy for malignant polyps following polypectomy: a systematic review and meta-analysis. International Journal of Colorectal Disease, 37 (5), 1035-1047. doi: 10.1007/s00384-022-04142-6 |
|
2021 Journal Article Protease-activated receptor-2 promotes osteogenesis in skeletal mesenchymal stem cells at the expense of adipogenesis: involvement of interleukin-6Sanaei, R., Kularathna, P. K., Taghavi, N., Hooper, J. D., Pagel, C. N. and Mackie, E. J. (2021). Protease-activated receptor-2 promotes osteogenesis in skeletal mesenchymal stem cells at the expense of adipogenesis: involvement of interleukin-6. Bone Reports, 15 101113, 101113. doi: 10.1016/j.bonr.2021.101113 |
